Source study found

Story checked

New diabetes pill orforglipron achieves uniform weight loss for women of all ages (opens in a new tab)

news-medical.net · 2026-09-28

Short answerEvidenceSource

Short answer

Mixed

Mixed.

2 claims go further than the study. One other point was not covered by the paper.

2 supported
2 overstated
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

news-medical.net · 2026-09-28

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Two of five claims overstate the study. Two of five check out. One claim the study doesn't address.

2 supported
2 overstated
1 not covered

Open claim evidence

The source study

1716-P: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2

Diabetes · 2026

Open source record

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedNew analyses to be presented at the EASD meeting suggest that the daily oral weight-loss/type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and life stages, including premenopausal, menopausal, and post-menopausal women.View evidenceHide evidence

Why this verdict

The abstract profile supports that this was a post-hoc ATTAIN-1/ATTAIN-2 analysis of orforglipron versus placebo in women stratified as pre-, peri-, or post-menopause, with significant body-weight reductions across menopausal-stage subgroups. However, the supplied abstract-level evidence does not establish that weight loss was statistically or clinically 'similar' across stages; subgroup-specific estimates, confidence intervals, and equivalence/interaction testing are not provided. Because this appears in headline framing, the 'similar weight loss' wording outruns what the abstract profile verifies.

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”

Claim 2 of 5OverstatedThe article reports that women given orforglipron had significant and similar body-weight reductions up to 14% across menopausal subgroups in both ATTAIN-1 and ATTAIN-2, and waist circumference reductions of up to 12.5 cm; up to 83% achieved at least 5% body-weight reduction versus 30% with placebo.View evidenceHide evidence

As statedup to 14% body-weight reduction; up to 12.5 cm waist-circumference reduction; 83% vs 30% achieving ≥5% body-weight reduction

Why this verdict

The profile supports significant body-weight reductions up to 14% and higher responder rates with orforglipron across menopausal-stage subgroups. But the story's numerical details do not match the profile: waist circumference reduction is reported in the profile as up to 11 cm, not 12.5 cm, and ≥5% weight-loss response is up to 83% with orforglipron versus 23% with placebo, not 30%. The claim also repeats 'similar' reductions across subgroups, which the abstract profile does not establish with subgroup-specific estimates or equivalence testing.

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”

Study evidence

Proportion achieving ≥5% body-weight reduction at 72 weeks was higher with OFG than placebo; abstract reports up to 83% with OFG vs 23% with placebo.Up to 83% (OFG) vs 23% (placebo) for ≥5% weight loss (as reported in abstract)

“...the proportion achieving BW reduction thresholds (≥5%, ≥10%, ≥15%, ≥20%) vs placebo were assessed at 72 weeks using the efficacy estimand.”

Claim 3 of 5Not coveredThe analyses were by Dr Hunter Thomas Hoffman of Eli Lilly and Company and colleagues, with Eli Lilly described as the sponsor of the study and manufacturer of orforglipron.View evidenceHide evidence

Why this verdict

The profile notes industry relationships in the abstract-level limitations, but it does not verify the named analyst Dr Hunter Thomas Hoffman, Eli Lilly's exact role as study sponsor, or Eli Lilly as manufacturer. These authorship/sponsorship details are therefore not verifiable from the supplied abstract-depth profile.

Claim 4 of 5SupportedThe article says orforglipron, an oral small-molecule non-peptide GLP-1 receptor agonist, was associated with significant body-weight reductions in the ATTAIN-1 and ATTAIN-2 studies, which involved people with overweight or obesity with or without diabetes.View evidenceHide evidence

As statedup to 14% body-weight reduction

Why this verdict

The profile supports that orforglipron is an oral non-peptide GLP-1 receptor agonist and that ATTAIN-1/ATTAIN-2 data showed significant body-weight reductions, reported up to 14%, in participants with overweight or obesity. The supplied profile does not fully detail every descriptor in the story, such as 'small-molecule' or the diabetes-status composition, but the main scientific claim and stated weight-loss magnitude are supported at abstract depth.

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”

Claim 5 of 5SupportedThe additional analysis evaluated orforglipron's effect on body weight in women by menopausal stage, using participants categorized as pre-, peri-, or post-menopausal and measuring changes in body weight, waist circumference, waist-to-height ratio, and proportions achieving weight-loss thresholds at 72 weeks.View evidenceHide evidence

As stated72 weeks; thresholds of ≥5%, ≥10%, ≥15%, and ≥20% body-weight reduction

Why this verdict

The profile directly supports that the additional post-hoc analysis evaluated orforglipron's effect in women by menopausal stage, categorized as pre-, peri-, or post-menopause, and assessed body weight, waist circumference, waist-to-height ratio, and proportions achieving ≥5%, ≥10%, ≥15%, and ≥20% body-weight reduction at 72 weeks using the efficacy estimand.

Study evidence

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”

Study evidence

“...the proportion achieving BW reduction thresholds (≥5%, ≥10%, ≥15%, ≥20%) vs placebo were assessed at 72 weeks using the efficacy estimand.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Waist-circumference result: the abstract profile reports reductions up to 11 cm with orforglipron versus placebo, not 12.5 cm.
The story covers waist circumference but gives a larger value, 12.5 cm, than the supplied profile's up-to-11-cm result.
From post-hoc subgroup analysis of randomized trials
Responder result: up to 83% of orforglipron-treated participants achieved ≥5% body-weight reduction versus 23% with placebo; higher proportions reached ≥5%, ≥10%, ≥15%, and ≥20% thresholds.
The story reflects the orforglipron 83% figure and the threshold endpoints, but it reports the placebo comparator as 30% rather than the profile's 23%, so the specific material result is not accurately reflected.
From post hoc menopausal-stage subgroup responder analysis
Waist-to-height ratio result: more orforglipron-treated participants moved to lower waist-to-height ratio categories than placebo.
The story says waist-to-height ratio was measured, but the supplied presentation does not report the paper's result that more orforglipron-treated participants shifted to lower waist-to-height ratio categories.
From post-hoc subgroup analysis of randomized trials; post hoc menopausal-stage subgroup responder analysis
Key limitation for the 'similar across menopausal stages' framing: the abstract profile does not provide equivalence testing, interaction testing, or subgroup-specific confidence intervals to demonstrate similar effects across stages.
The story frames the result as similar weight loss across menopausal stages, but the supplied profile only supports significant reductions across subgroups and does not show evidence needed to verify similarity.
From post-hoc subgroup analysis of randomized trials

5 things the story did carry across

Central design: post-hoc subgroup analysis of female participants from ATTAIN-1 and ATTAIN-2 randomized placebo-controlled trials, comparing orforglipron with placebo by menopausal status at 72 weeks.
Continuous adiposity outcomes: body weight, waist circumference, and waist-to-height ratio were assessed using the 72-week efficacy estimand.
Body-weight result: orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% at 72 weeks.
Key limitation: the analysis was explicitly post hoc, so menopausal-stage subgroup findings are exploratory and may not have been prespecified.
Industry involvement/conflicts: the profile reports industry relationships among authors; the story notes Eli Lilly as sponsor/manufacturer.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEvaluate whether orforglipron vs placebo reduces body weight and waist-related outcomes in women, stratified by menopausal stage, using post hoc subgroup analyses of ATTAIN-1 and ATTAIN-2 at 72 weeks (efficacy estimand).post-hoc subgroup analysis of randomized trialsExpand

In plain English

Post-hoc subgroup analysis of ATTAIN-1 and ATTAIN-2 randomized trials examined orforglipron (OFG) versus placebo in women with overweight/obesity stratified by menopausal stage (pre-, peri-, post-) using a 72-week efficacy estimand. The abstract reports significant reductions in body weight (up to 14%) and waist circumference (up to 11 cm) with OFG versus placebo (p<0.001), higher proportions achieving prespecified weight-loss thresholds (e.g., up to 83% achieving ≥5% vs 23% with placebo), and greater movement to lower waist-to-height ratio categories with OFG.

Key findings

Orforglipron produced statistically significant body-weight reductions versus placebo across menopausal-stage subgroups, reported as up to 14% weight loss at 72 weeks (p<0.001).Up to 14% reduction
Orforglipron was associated with reductions in waist circumference versus placebo, reported as up to 11 cm decrease at 72 weeks (p<0.001).Up to 11 cm decrease

“This post-hoc analysis evaluates OFG’s effect on BW in women by menopausal stage.”

What this piece can’t prove

Analysis is explicitly described as post-hoc; subgroup findings may be exploratory and not prespecified.
Abstract does not report subgroup-specific sample sizes, confidence intervals, or detailed statistical model specifications.

2 further details could not be confirmed from the summary.

2secondary dataAssess categorical responder outcomes (proportions achieving ≥5%, ≥10%, ≥15%, ≥20% weight loss) and shifts in waist-to-height ratio categories by menopausal stage for orforglipron vs placebo.post hoc menopausal-stage subgroup responder analysisExpand

In plain English

Post-hoc menopausal-stage subgroup responder analysis of female participants from the ATTAIN-1 and ATTAIN-2 trials assessing categorical weight-loss responder rates (≥5%, ≥10%, ≥15%, ≥20%) and shifts in waist-to-height ratio (WtHR) categories at 72 weeks using the efficacy estimand. The abstract reports substantially higher proportions achieving responder thresholds with orforglipron (OFG) versus placebo (PBO), including up to 83% achieving ≥5% weight loss with OFG versus 23% with PBO, and more participants on OFG shifting to lower WtHR categories. Analyses are post hoc and the abstract does not provide subgroup-specific counts, full numerical breakdowns by menopausal stage, or detailed statistical methods for responder and shift analyses.

Key findings

Proportion achieving ≥5% body-weight reduction at 72 weeks was higher with OFG than placebo; abstract reports up to 83% with OFG vs 23% with placebo.Up to 83% (OFG) vs 23% (placebo) for ≥5% weight loss (as reported in abstract)
Significantly higher proportions achieved prespecified categorical weight-loss thresholds (≥5%, ≥10%, ≥15%, ≥20%) with OFG versus placebo (reported p<0.001).p<0.001 (reported for comparisons across thresholds)

“...the proportion achieving BW reduction thresholds (≥5%, ≥10%, ≥15%, ≥20%) vs placebo were assessed at 72 weeks using the efficacy estimand.”

What this piece can’t prove

Post-hoc subgroup analysis: findings reported by menopausal stage are secondary and exploratory in nature.
Abstract-only reporting: no subgroup sample sizes, confidence intervals, or detailed numerical results for each menopausal stage or each responder threshold are provided.
Statistical details missing in abstract: methods for multiplicity control, specific statistical tests, covariate adjustment, and handling of missing data are not described.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer